Stocks › GILD
GILEAD SCIENCES, INC.
GILD·Nasdaq·
United States·USD
$166.43
-0.10 (-0.06%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
GILD
GILEAD SCIENCES, INC. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
GILDS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of GILD by members of U.S. Congress · 284 on record · 16 in the last 12 months
Whale Activity
Position changes in GILD reported for 2026-09-30 by 2488 institutional filers
- Increased938
- New224
- Held291
- Decreased807
- Closed128
- No prior filing100
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 125.2M | $18.67B | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 81.2M | $12.10B | increased |
| STATE STREET CORP | 61.0M | $9.09B | decreased |
| FMR LLC | 58.3M | $8.68B | decreased |
| Invesco Ltd. | 38.7M | $5.76B | decreased |
| Capital World Investors | 35.9M | $5.36B | decreased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 35.7M | $5.32B | increased |
| GEODE CAPITAL MANAGEMENT, LLC | 30.2M | $4.49B | increased |
| PRICE T ROWE ASSOCIATES INC /MD/ | 27.7M | $4.12B | decreased |
| Capital Research Global Investors | 24.0M | $3.57B | increased |
| MORGAN STANLEY | 23.8M | $3.54B | decreased |
| JPMORGAN CHASE & CO | 23.1M | $3.49B | increased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Net shares bought (+) or sold (−) on the open market by GILD insiders, by quarter · Form 4
Recent Insider Transactions
4,914 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Mercier JohannaChief Comm & Corp Aff Officer | Sale | −900 | $171.69 | $155K | Nov 16, 2026 | Form 4 ↗ |
| Mercier JohannaChief Comm & Corp Aff Officer | Sale | −13.9K | $169.97 | $2.4M | Nov 16, 2026 | Form 4 ↗ |
| Mercier JohannaChief Comm & Corp Aff Officer | Sale | −13.2K | $171.09 | $2.3M | Nov 16, 2026 | Form 4 ↗ |
| Dickinson Andrew DChief Financial Officer | Sale | −3,000 | $171.47 | $514K | Nov 16, 2026 | Form 4 ↗ |
| Kramer Kelly A.Director · Director | Sale | −4,700 | $170.49 | $801K | Nov 12, 2026 | Form 4 ↗ |
| Kramer Kelly A.Director · Director | Sale | −3,800 | $169.44 | $644K | Nov 12, 2026 | Form 4 ↗ |
| Kramer Kelly A.Director · Director | Sale | −200 | $171.44 | $34K | Nov 12, 2026 | Form 4 ↗ |
| Kramer Kelly A.Director · Director | Sale | −1,676 | $168.23 | $282K | Nov 12, 2026 | Form 4 ↗ |
| Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp | Sale | −3,399 | $164.11 | $558K | Nov 6, 2026 | Form 4 ↗ |
| O'Day Daniel PatrickChairman & CEO · Director | Sale | −9,810 | $175.17 | $1.7M | Nov 5, 2026 | Form 4 ↗ |
| O'Day Daniel PatrickChairman & CEO · Director | Sale | −102.6K | $175.16 | $18.0M | Nov 4, 2026 | Form 4 ↗ |
| O'Day Daniel PatrickChairman & CEO · Director | Sale | −7,796 | $170.35 | $1.3M | Nov 2, 2026 | Form 4 ↗ |
| O'Day Daniel PatrickChairman & CEO · Director | Sale | −2,000 | $171.06 | $342K | Nov 2, 2026 | Form 4 ↗ |
| O'Day Daniel PatrickChairman & CEO · Director | Sale | −1,904 | $169.27 | $322K | Nov 2, 2026 | Form 4 ↗ |
| O'Day Daniel PatrickChairman & CEO · Director | Sale | −1,700 | $168.10 | $286K | Nov 2, 2026 | Form 4 ↗ |
| O'Day Daniel PatrickChairman & CEO · Director | Sale | −1,600 | $167.40 | $268K | Nov 2, 2026 | Form 4 ↗ |
| O'Day Daniel PatrickChairman & CEO · Director | Sale | −15.9K | $175.25 | $2.8M | Oct 30, 2026 | Form 4 ↗ |
| Mercier JohannaChief Comm & Corp Aff Officer | Sale | −3,000 | $156.22 | $469K | Oct 15, 2026 | Form 4 ↗ |
| Dickinson Andrew DChief Financial Officer | Sale | −3,000 | $156.22 | $469K | Oct 15, 2026 | Form 4 ↗ |
| O'Day Daniel PatrickChairman & CEO · Director | Sale | −3,000 | $148.63 | $446K | Oct 1, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding GILD · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 39.4M | $4.98B | 0.22% | Jun 30, 2026 |
| VANGUARD 500 INDEX FUND VANGUARD INDEX FUNDS | 32.2M | $4.06B | 0.24% | Jun 30, 2026 |
| Invesco QQQ Trust, Series 1 | 26.4M | $3.33B | 0.68% | Jun 30, 2026 |
| Fidelity 500 Index Fund Fidelity Concord Street Trust | 16.1M | $2.36B | 0.27% | Aug 31, 2026 |
| Dodge & Cox Stock Fund Dodge & Cox Funds | 17.3M | $2.18B | 1.84% | Jun 30, 2026 |
| iShares Core S&P 500 ETF iShares Trust | 17.1M | $2.16B | 0.24% | Jun 30, 2026 |
| Income Fund of America | 15.5M | $2.02B | 1.36% | Jul 31, 2026 |
| State Street(R) SPDR(R) S&P 500(R) ETF Trust | 15.0M | $1.90B | 0.24% | Jun 30, 2026 |
| VANGUARD VALUE INDEX FUND VANGUARD INDEX FUNDS | 11.8M | $1.49B | 0.59% | Jun 30, 2026 |
| Fidelity Contrafund | 11.4M | $1.44B | 0.80% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list GILD's shares (CUSIP 375558103), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
No 13D/13G beneficial-ownership filings on record.
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming gilead sciences as client
- GILEAD SCIENCES, INC.GILEAD SCIENCES INC · 2026 Q3 · TRD, BUD, HCR, MMM$2.3M
Filing ↗ - GILEAD SCIENCES, INC.GILEAD SCIENCES INC · 2026 Q3 · TRD, HCR, MMM, CPT$6.6M
Filing ↗ - TARPLIN, DOWNS & YOUNG, LLCGILEAD SCIENCES, INC. · 2026 Q3 · BUD, HCR, MMM$80K
Filing ↗ - FARRAGUT PARTNERS LLPGILEAD SCIENCES INC. · 2026 Q3 · MMM, HCR$80K
Filing ↗ - MILLER STRATEGIES, LLCGILEAD SCIENCES, INC. · 2026 Q3 · HCR, BUD, MMM$150K
Filing ↗
Government Contracts
Federal awards to gilead sciences · USAspending
$15KAwarded · 1 contract on record
- Department of Veterans AffairsLENACAPAVIR (SUNLENCA)$15K
May 14, 2025 · ↗
U.S. Patents
Recent USPTO applications naming GILEAD SCIENCES, INC.
No USPTO patent applications found for GILEAD SCIENCES, INC..
Annual Financials
From GILD's 10-K filings · XBRL
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $29.44B | $28.75B | $27.12B | $27.28B | $27.30B |
| Operating income | $10.02B | $1.66B | $7.61B | $7.33B | $9.92B |
| Net income | $8.51B | $480.0M | $5.67B | $4.59B | $6.22B |
| Diluted EPS | $6.78 | $0.38 | $4.50 | $3.64 | $4.93 |
| Operating cash flow | $10.02B | $10.83B | $8.01B | $9.07B | $11.38B |
| Cash and equivalents | n/a | n/a | n/a | $5.41B | $5.34B |
| Total assets | $59.02B | $58.99B | $62.13B | $63.17B | $67.95B |
| Shareholders' equity | $22.70B | $19.33B | $22.83B | $21.24B | $21.07B |
As GILEAD SCIENCES, INC. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 24, 2026 ↗
Stock Splits
Every split and reverse split in the price history
- 2-for-1Stock splitJan 28, 2013
- 2-for-1Stock splitJun 25, 2007
- 2-for-1Stock splitSep 7, 2004
- 2-for-1Stock splitMar 8, 2002
- 2-for-1Stock splitFeb 22, 2001
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 2.02, 9.01Results of operationsOct 29, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 4, 2026
EDGAR ↗ - 8-K · Items 1.01, 2.03, 8.01, 9.01Material agreement · Direct financial obligation · Other eventsMay 20, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 7, 2026
EDGAR ↗ - 8-K · Items 5.07, 9.01Shareholder voteMay 4, 2026
EDGAR ↗ - 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsApr 28, 2026
EDGAR ↗ - 8-K · Items 1.01, 7.01, 9.01Material agreement · Reg FD disclosureFeb 23, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsFeb 10, 2026
EDGAR ↗ - 8-K · Items 5.02Officer / director changeNov 19, 2025
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsOct 30, 2025
EDGAR ↗
About GILEAD SCIENCES, INC.
From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersFOSTER CITY, CA
IncorporatedDE
SEC CIK0000882095 ↗
Former namesGILEAD SCIENCES INC









